GEHC: Leadership change · Company disclosure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Pascal Desroches to serve as a director of the Company, effective January 4, 2027. The Board also appointed Mr. Desroches as a member of the Audit Committee and the Talent, Culture, and Compensation Committee of the Board, effective January 4, 2027. Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 19, 2026. The Company will also enter into an indemnification agreement with Mr. Desroches. The form of indemnification agreement is included as Exhibit 10.3 to the Company’s Annual Report on Form 10-K filed with the SEC on February 4, 2026. There is no arrangement or understanding between Mr. Desroches and any other person pursuant to which he was selected as a director. There are no transactions between Mr. Desroches and the Company that would be reportable under Item 404(a) of Regulation S-K. Item 7.01 Regulation FD Disclosure. On September 22, 2026, the Company issued a press release announcing the appointment of Pascal Desroches to its Board. A copy of the press release is furnished as Exhibit 99. The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section a